Your session is about to expire
← Back to Search
Neurotoxin
DAXI 240 U for Plantar Fibroma
Phase 2
Waitlist Available
Research Sponsored by Revance Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 weeks
Summary
The specific aim of the study is to compare the safety and efficacy of a single administration of DaxibotulinumtoxinA for Injection versus placebo for managing plantar fasciitis.
Eligible Conditions
- Plantar Fibroma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 16 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Improvement in the American Orthopaedic Foot and Ankle Score (AOFAS)
Secondary study objectives
Reduction in the visual analog pain score for the foot
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: DAXI 240 UExperimental Treatment1 Intervention
DaxibotulinumtoxinA for injection for the treatment of plantar fasciitis (PF) with 240 U
Group II: PlaceboPlacebo Group1 Intervention
Placebo Intramuscular injection
Find a Location
Who is running the clinical trial?
Revance Therapeutics, Inc.Lead Sponsor
30 Previous Clinical Trials
6,538 Total Patients Enrolled
Wake Forest University Health SciencesOTHER
1,389 Previous Clinical Trials
2,547,019 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger